Join our experienced panelists for a review of key takeaways from the FDA’s 2024 drug and device advertising and promotion enforcement letters.

Other topics include:

• FDA’s new “Addressing Misinformation” guidance;
• FDA’s “CCN” final rule for presentation of the major statement in DTC prescription drug ads and related DTC TV trends;
• FTC updates;
• OPDP research initiatives; and
• predictions for what may be expected in 2025. 

For questions, contact Christine Lieber.